Submit Your Feeds

Business News • PR NewsWire • Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine

Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine
Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine

TARRYTOWN, N.Y. and PARIS, Oct. 1, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announce that detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies evaluating investigational Dupixent® (dupilumab) in adult...

View More : http://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-positive-dupixent-dupilumab-phase-3-atopic-dermati...
Releted News by prnewswire
Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine
La Conferencia de Negocios Hispanos de Maryland ostenta un elenco estelar
Wells Fargo and Habitat for Humanity of Washington, D.C. Partner on Special Volunteer Events to Build Affordable Housing
Eagamers Best Place to Purchase FIFA 17 Ultimate Team Coins for Low and Affordable Rates
Home Sitemap Contact Us
© businessNewsNewsNews.com